Almac Sciences launches large scale GMP peptide manufacturing

Almac Sciences has extended its capacity for GMP production of peptides to multikilo scale following the commissioning of a £500,000 package of assets at its sites in Northern Ireland and Scotland.

New investment at the large scale multi-product site in Craigavon, Northern Ireland, includes automated peptide synthesis equipment, preparative HPLC and a freeze-drying suite; while the production and r&d centre in Edinburgh, Scotland, now boasts new equipment for small-scale peptide synthesis. The company therefore now offers production of 200 peptides a month for drug discovery purposes, rapid clinical supply for Phases I and II, and the ability to make GMP peptides up to 170 amino acids in length using linear synthesis.

These developments mark a further link in the chain of Almac's 'making connections' strategy. According to Dr David Moody, vp commercial operations, there are a number of projects now in Phase I involving the conjugation of a peptide as a carrier with a cytotoxic, both manufactured to GMP standards. The company is unique in its ability to add to this radiolabelling using its proprietary tagging technology, he believes.

Featured Companies

Almac Group (more information, website)